Worth reading
64In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Decision and Details
Decision to grant a patent in Japan for a combination of a humanized DLK-1 antibody and an FGFR4 inhibitor
Decision22 June 2026 (the date the decision to grant the patent was received)
Going forwardApplications are also pending in the United States, Europe, China and other jurisdictions. For CBA-1205, the company aims to out-license the product to a pharmaceutical company using safety and preliminary efficacy data obtained from a domestic Phase 1 clinical trial.
Quantity / scalePatent application number: 特願2022-555609
Reason
To strengthen the intellectual property platform supporting development and out-licensing activities
Impact on Business Performance
This matter will have no impact on results for the fiscal year ending December 2026.
| Item | Details |
|---|---|
| Matter Covered | Decision to grant a patent in Japan for a combination of a humanized DLK-1 antibody and an FGFR4 inhibitor |
| Decision Date | 22 June 2026 (the date the decision to grant the patent was received) |
| Quantity / scale | Patent application number: 特願2022-555609 |
| Impact on Business Performance | This matter will have no impact on results for the fiscal year ending December 2026. |
| Reason | To strengthen the intellectual property platform supporting development and out-licensing activities |
| Future plans | Applications are also pending in the United States, Europe, China and other jurisdictions. For CBA-1205, the company aims to out-license the product to a pharmaceutical company using safety and preliminary efficacy data obtained from a domestic Phase 1 clinical trial. |
Items this document does not state (6)
Decision-Making BodyImplementation DatePeriod CoveredAmountGoverning RuleRelated previous disclosures
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explains that the decision to grant the patent will strengthen its intellectual property platform supporting development and out-licensing activities.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.